Attomarker is a British company focused on nanophotonic biochemical testing. It was founded in 2008, and spun out from Professor Andrew Shaw’s research group at the University of Exeter. It has won numerous prestigious awards for innovation and been awarded grants for research from the UK Government due to the importance of its work.
Attomarker works in the personalised medicine market and is committed to providing gold-standard rapid diagnostics to enable better and more timely decisions about health and health interventions.
It has a significant pipeline of tests and is currently focused on four of the most important global health challenges: COVID-19, Obesity, Food Allergy and Antimicrobial Resistance (AMR).
The core technology can rapidly measure multiple biomarkers in a low volume of blood or saliva to provide a personal immunity or health profile: up to 20 tests in 7 minutes. The data can be used by patients to make more informed decisions about their health, wellbeing and protection, and by healthcare professionals to determine a personalised patient healthcare pathway across multiple healthcare settings at the bedside, in the operating theatre, in the pharmacy and at home.
Currently the Company’s products are available in the UK, Cayman Islands and Malta, with plans to roll out on a more global footing in the year ahead. It’s an exciting time for Attomarker but perhaps even more so for the patients served by its innovative gold-based nanophotonic technology.